XL MYC amp consists of an orange-labeled probe hybridizing to the MYC gene region at 8q24.21 and a green-labeled probe hybridizing to the centromere of chromosome 8.

Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.

Amplification of MYC has been described in many types of tumor, including breast, cervical and colon cancers, as well as in squamous cell carcinomas of the head and neck, myeloma, non-Hodgkin lymphoma, gastric adenocarcinomas and ovarian cancer. MYC is the most frequently amplified oncogene and the elevated expression of its gene product correlates with tumor aggression and poor clinical outcome.
The proto-oncogene MYC, located at 8q24.1, encodes a nuclear phosphoprotein transcription factor which has an integral role in a variety of cellular processes, such as cell cycle progression, proliferation, metabolism, adhesion, differentiation, and apoptosis.

Clinical Applications

• Solid Tumors (Solid Tumors)

XL MYC amp hybridized to breast cancer tissue. Multiple orange signals indicate amplification of MYC.

• Rummukainen et al (2001) Mod Pathol 14:1030-1035
• Blancato et al (2004) Br J Cancer 90:1612-1619
• Singhi et al (2012) Mod Pathol 25:378-387